Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 5
HOS-086159 · Präparat HOS-083284
Microsomal Lomitapide Increased plasma concentrations of lomitapide
triglyceride transfer (see section 4.5).
protein (MTTP)
inhibitor
PDE5 inhibitors Avanafil Increased plasma concentrations of avanafil
(see section 4.4. and 4.5).
Sildenafil Contraindicated when used for the treatment of
pulmonary arterial hypertension (PAH) only.
Increased plasma concentrations of sildenafil.
Thereby, increasing the potential for sildenafil-
associated adverse events (which include
hypotension and syncope). See section 4.4 and
section 4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of vardenafil
(see section 4.4. and 4.5).
Sedatives/hypnotics Clorazepate, diazepam, Increased plasma concentrations of clorazepate,
estazolam, flurazepam, diazepam, estazolam, flurazepam, oral
oral midazolam and midazolam and triazolam. Thereby, increasing
triazolam the risk of extreme sedation and respiratory
depression from these agents. (For caution on
parenterally administered midazolam, see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) lomitapide (HOS-086160) clorazepate (HOS-086164) diazepam (HOS-085904) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) flurazepam (HOS-086166) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 08cb4669d26fd4170f47a5f99fcf18bde7e922c35f378d07e3e1c1cab8b82945 · Zeichen 6375–8447 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 37
HOS-086390 · Präparat HOS-083284
Microsomal Lomitapide Increased plasma concentrations of lomitapide
triglyceride transfer (see section 4.5).
protein (MTTP)
inhibitor
PDE5 inhibitor Avanafil Increased plasma concentrations of avanafil
(see section 4.4. and 4.5).
Sildenafil Contraindicated when used for the treatment of
pulmonary arterial hypertension (PAH) only.
Increased plasma concentrations of sildenafil.
Thereby, increasing the potential for sildenafil-
associated adverse events (which include
hypotension and syncope). See section 4.4 and
section 4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of vardenafil
(see section 4.4. and 4.5).
Sedatives/hypnotics Clorazepate, diazepam, Increased plasma concentrations of clorazepate,
estazolam, flurazepam, diazepam, estazolam, flurazepam, oral
oral midazolam and midazolam and triazolam. Thereby, increasing
triazolam the risk of extreme sedation and respiratory
depression from these agents. (For caution on
parenterally administered midazolam, see
section 4.5.).
Ritonavir medicinal product level decreased
Herbal Preparation St. John’s Wort Herbal preparations containing St John’s wort
(Hypericum perforatum) due to the risk of
decreased plasma concentrations and reduced
clinical effects of ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) lomitapide (HOS-086160) clorazepate (HOS-086164) diazepam (HOS-085904) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) flurazepam (HOS-086166) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 235db82cd2afd722d3066659d7d625c3a96a3162e89ca0b2b4a6f83e7ca9d95d · Zeichen 6173–8675 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 21–22
HOS-086320 · Präparat HOS-083284
21
Ritonavir effects on Non-antiretroviral Co-administered Medicinal Products
Co-administered Medicinal Products Dose of Co- Dose of Effect on Co- Effect on Co-
administered NORVIR (mg) administered administered
Medicinal Products Medicinal Medicinal Products
(mg) Products Cmax
AUC
Triazolam 0.125, single dose 200, 4 doses ↑ > 20 fold ↑ 87%
Ritonavir co-administration is likely to result in increased plasma concentrations of
triazolam and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triazolam (HOS-086168)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 039161a22dea2643b1fdec1594d7bd3d6e92739bb7c122ff67c4c52cb2415c31 · Zeichen 51558–52533 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 54
HOS-086483 · Präparat HOS-083284
Triazolam 0.125, single dose 200, 4 ↑ > 20 fold ↑ 87%
doses
Ritonavir co-administration is likely to result in increased plasma concentrations of
triazolam and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triazolam (HOS-086168)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 9a5a169f2949c39b0a7142f7f1513bc21f456cb65604ae49b2e8505a7b1f7c5f · Zeichen 53527–53953 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.3 · PDF-Seite 6
HOS-108817 · Präparat HOS-093083
HMG Co-A Reductase Lovastatin, simvastatin Increased plasma concentrations of
Inhibitors lovastatin and simvastatin; thereby,
increasing the risk of myopathy
including rhabdomyolysis (see section
4.5).
Microsomal Lomitapide Increased plasma concentrations of
triglyceride transfer lomitapide (see section 4.5).
protein (MTTP)
inhibitor
Phosphodiesterase Avanafil Increased plasma concentrations of
(PDE5) inhibitors avanafil (see sections 4.4 and 4.5).
Sildenafil Contraindicated when used for the
treatment of pulmonary arterial
hypertension (PAH) only. Increased
plasma concentrations of sildenafil.
Thereby, increasing the potential for
sildenafil-associated adverse events
(which include hypotension and
syncope). See section 4.4 and section
4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of
vardenafil (see sections 4.4 and 4.5)
Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral
midazolam and triazolam. Thereby,
increasing the risk of extreme sedation
and respiratory depression from these
agents.
For caution on parenterally administered
midazolam, see section 4.5.
Lopinavir/ritonavir medicinal product level decreased
Herbal products St. John’s wort Herbal preparations containing St John’s
wort (Hypericum perforatum) due to the
risk of decreased plasma concentrations
and reduced clinical effects of lopinavir
and ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c938be9b188cbabde88400ddb49de67c2831b955f638dc8fa5306b13f1652968 · Zeichen 6187–9289 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 43–44
HOS-108990 · Präparat HOS-093083
43
Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral
midazolam and triazolam. Thereby,
increasing the risk of extreme sedation
and respiratory depression from these
agents.
For caution on parenterally
administered midazolam, see section
4.5.
Lopinavir/ritonavir medicinal product level decreased
Herbal products St. John’s wort Herbal preparations containing St
John’s wort (Hypericum perforatum)
due to the risk of decreased plasma
concentrations and reduced clinical
effects of lopinavir and ritonavir (see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 92a02386fc1a77aef711a4b1e6d441f26b16e78482f67469b16622696dc32d8d · Zeichen 8625–9989 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 78–79
HOS-109064 · Präparat HOS-093083
78
Phosphodiesterase Avanafil Increased plasma concentrations of
(PDE5) inhibitors avanafil (see sections 4.4 and 4.5)
Sildenafil Contraindicated when used for the
treatment of pulmonary arterial
hypertension (PAH) only. Increased
plasma concentrations of sildenafil.
Thereby, increasing the potential for
sildenafil-associated adverse events
(which include hypotension and syncope).
See section 4.4 and section 4.5 for
co-administration of sildenafil in patients
with erectile dysfunction.
Vardenafil Increased plasma concentrations of
vardenafil (see sections 4.4 and 4.5)
Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral
midazolam and triazolam. Thereby,
increasing the risk of extreme sedation
and respiratory depression from these
agents.
For caution on parenterally administered
midazolam, see section 4.5.
Lopinavir/ritonavir medicinal product level decreased
Herbal products St. John’s wort Herbal preparations containing St John’s
wort (Hypericum perforatum) due to the
risk of decreased plasma concentrations
and reduced clinical effects of lopinavir
and ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 5fd5fb90c510eab32eaadc8b17bd2236491bc4b4553317338a4ddfd4a5d22f67 · Zeichen 7137–9814 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-109472 · Präparat HOS-093201
Other benzodiazepines Although not studied, voriconazole
(including but not limited to: is likely to increase the plasma
triazolam, alprazolam) concentrations of other
benzodiazepines that are
metabolised by CYP3A4 and lead
to a prolonged sedative effect.
Cardiovascular agents
Ivabradine Although not studied, increased Contraindicated (see section
[CYP3A4 substrates] plasma concentrations of 4.3)
ivabradine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Mavacamten Although not studied, voriconazole Refer to the mavacamten
[CYP2C19, CYP3A4 and is likely to increase the plasma summary of product
CYP2C9 substrate] concentrations of mavacamten with characteristics (SmPC) for more
increased risk of heart failure. information.
Cystic fibrosis transmembrane conductance regulator potentiators
Ivacaftor Although not studied, voriconazole Dose reduction of ivacaftor is
[CYP3A4 substrate] is likely to increase the plasma recommended.
concentrations of ivacaftor with
risk of increased adverse reactions.
Ergot derivatives
Ergot alkaloids (including but Although not studied, voriconazole Contraindicated (see section
not limited to: ergotamine and is likely to increase the plasma 4.3)
dihydroergotamine) concentrations of ergot alkaloids
[CYP3A4 substrates] and lead to ergotism.
GI motility agents
Cisapride Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of cisapride 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Herbal medicines
St. John’s Wort In an independent published study, Contraindicated (see section
[CYP450 inducer; Voriconazole AUC0- 59% 4.3)
P-gp inducer]
300 mg TID (coadministered
with voriconazole 400 mg
single dose)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) alprazolam (HOS-086171) mavacamten (HOS-109474) ergot alkaloids (HOS-108807) lead (HOS-085592) ivacaftor (HOS-109475) ivabradine (HOS-109426) ergotamine (HOS-086154) triazolam (HOS-086168) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 13738601987c7c15c8b764a4e09817857affdc23295d0c554fe878df6b4cef0a · Zeichen 20515–22914 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 46
HOS-109546 · Präparat HOS-093201
Other benzodiazepines Although not studied, voriconazole
(including but not limited to: is likely to increase the plasma
triazolam, alprazolam) concentrations of other
benzodiazepines that are
metabolised by CYP3A4 and lead
to a prolonged sedative effect.
Cardiovascular agents
Ivabradine Although not studied, increased Contraindicated (see section
[CYP3A4 substrates] plasma concentrations of 4.3)
ivabradine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Mavacamten Although not studied, voriconazole Refer to the mavacamten
[CYP2C19, CYP3A4 and is likely to increase the plasma summary of product
CYP2C9 substrate] concentrations of mavacamten with characteristics (SmPC) for more
increased risk of heart failure. information.
Cystic fibrosis transmembrane conductance regulator potentiators
Ivacaftor Although not studied, voriconazole Dose reduction of ivacaftor is
[CYP3A4 substrate] is likely to increase the plasma recommended.
concentrations of ivacaftor with
risk of increased adverse reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alprazolam (HOS-086171) mavacamten (HOS-109474) lead (HOS-085592) ivacaftor (HOS-109475) ivabradine (HOS-109426) triazolam (HOS-086168)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 7cc4a837ff3a25ae5dcbb2d1f1525086d542db6220d9ced57b82c1de87716f54 · Zeichen 20947–22424 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 79
HOS-109612 · Präparat HOS-093201
Other benzodiazepines Although not studied, voriconazole
(including but not limited to: is likely to increase the plasma
triazolam, alprazolam) concentrations of other
benzodiazepines that are
metabolised by CYP3A4 and lead
to a prolonged sedative effect.
Cardiovascular agents
Ivabradine Although not studied, increased Contraindicated (see section
[CYP3A4 substrates] plasma concentrations of 4.3)
ivabradine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Mavacamten Although not studied, voriconazole Refer to the mavacamten
[CYP2C19, CYP3A4 and is likely to increase the plasma summary of product
CYP2C9 substrate] concentrations of mavacamten with characteristics (SmPC) for more
increased risk of heart failure. information.
Cystic fibrosis transmembrane conductance regulator potentiators
Ivacaftor Although not studied, voriconazole Dose reduction of ivacaftor is
[CYP3A4 substrate] is likely to increase the plasma recommended.
concentrations of ivacaftor with
risk of increased adverse reactions.
Ergot derivatives
Ergot alkaloids (including but Although not studied, voriconazole Contraindicated (see section
not limited to: ergotamine and is likely to increase the plasma 4.3)
dihydroergotamine) concentrations of ergot alkaloids
[CYP3A4 substrates] and lead to ergotism.
GI motility agents
Cisapride Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of cisapride 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Herbal medicines
St. John’s Wort In an independent published study, Contraindicated (see section
[CYP450 inducer; Voriconazole AUC0- 59% 4.3)
P-gp inducer]
300 mg TID (coadministered
with voriconazole 400 mg
single dose)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) alprazolam (HOS-086171) mavacamten (HOS-109474) ergot alkaloids (HOS-108807) lead (HOS-085592) ivacaftor (HOS-109475) ivabradine (HOS-109426) ergotamine (HOS-086154) triazolam (HOS-086168) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 13738601987c7c15c8b764a4e09817857affdc23295d0c554fe878df6b4cef0a · Zeichen 20545–22944 im Abschnitt
Gegenanzeigen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-112044 · Präparat HOS-093615
Co-administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome
P450 and have narrow therapeutic windows (e.g., quetiapine, lurasidone, alfuzosin, astemizole,
terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, midazolam administered orally (for
caution on parenterally administered midazolam, see section 4.5), lomitapide, and ergot alkaloids,
particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) cisapride (HOS-085610) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 7b7b0f048824fcb784b546989cbc26fbf98af81b02e5d50ce08dc589e2545d88 · Zeichen 636–1122 im Abschnitt
Gegenanzeigen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.3 · PDF-Seite 40
HOS-112152 · Präparat HOS-093615
Co-administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome
P450 and have narrow therapeutic windows (e.g., quetiapine, alfuzosin, astemizole, terfenadine,
cisapride, pimozide, quinidine, lurasidone, bepridil, triazolam, midazolam administered orally (for
caution on parenterally administered midazolam, see section 4.5), lomitapide and ergot alkaloids,
particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) cisapride (HOS-085610) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage e442989da36600ebf7f8db27c93ddf7cb3e10a213eeefa38bb99d1990671ccee · Zeichen 495–980 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-112050 · Präparat HOS-093615
Atazanavir is metabolised in the liver through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ is
contraindicated with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic
index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine,
bepridil, triazolam, orally administered midazolam, lomitapide, and ergot alkaloids, particularly
ergotamine and dihydroergotamine (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfuzosin (HOS-086139) cisapride (HOS-085610) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 85781e83a9b10bfbdd236ee812040730eb3a9b3f74e06aebc98fed6a6305ec35 · Zeichen 315–760 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 24
HOS-112118 · Präparat HOS-093615
The mechanism of interaction is CYP3A4
and UGT1A1 inhibition.
Concentrations of atazanavir (when given
with ritonavir) were not significantly
affected.
Methadone, stable maintenance No significant effect on methadone No dosage adjustment is necessary
dose concentrations was observed. Given that if methadone is co-administered
(atazanavir 400 mg once daily) low dose ritonavir (100 mg twice daily) with REYATAZ.
has been shown to have no significant
effect on methadone concentrations, no
interaction is expected if methadone is co-
administered with REYATAZ, based on
these data.
PULMONARY ARTERIAL HYPERTENSION
PDE5 Inhibitors
Sildenafil Co-administration with REYATAZ may A safe and effective dose in
result in increased concentrations of the combination with REYATAZ has
PDE5 inhibitor and an increase in PDE5- not been established for sildenafil
inhibitor-associated adverse events. when used to treat pulmonary
arterial hypertension. Sildenafil,
The mechanism of interaction is CYP3A4 when used for the treatment of
inhibition by atazanavir and/or ritonavir. pulmonary arterial hypertension, is
contraindicated (see section 4.3).
SEDATIVES
Benzodiazepines
Midazolam Midazolam and triazolam are extensively Co-administration of REYATAZ
Triazolam metabolised by CYP3A4. Co- with triazolam or orally
administration with REYATAZ may cause administered midazolam is
a large increase in the concentration of contraindicated (see section 4.3),
these benzodiazepines. No drug interaction whereas caution should be used
study has been performed for the co- with co-administration of
administration of REYATAZ with REYATAZ and parenteral
benzodiazepines. Based on data for other midazolam. If REYATAZ is co-
CYP3A4 inhibitors, plasma concentrations administered with parenteral
of midazolam are expected to be midazolam, it should be done in an
significantly higher when midazolam is intensive care unit (ICU) or similar
given orally. Data from concomitant use of setting which ensures close clinical
parenteral midazolam with other protease monitoring and appropriate medical
inhibitors suggest a possible 3-4-fold management in case of respiratory
increase in midazolam plasma levels. depression and/or prolonged
sedation. Dosage adjustment for
midazolam should be considered,
especially if more than a single
dose of midazolam is administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) protease (HOS-085623) sildenafil (HOS-086162) ritonavir (HOS-084521) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage be486e27c0486d810d40c1b37da9b7f69c7a35ad1fcade19cc1e1d57a1b71724 · Zeichen 71400–75434 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 44
HOS-112157 · Präparat HOS-093615
Atazanavir is metabolised in the liver through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ
with ritonavir is contraindicated with medicinal products that are substrates of CYP3A4 and have a
narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride,
pimozide, quinidine, bepridil, triazolam, orally administered midazolam, lomitapide, and ergot
alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3). Co-administration of
REYATAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed-dose
combination is contraindicated because of the increase in grazoprevir and elbasvir plasma
concentrations and potential for the increase in risk of ALT elevations associated with increased
grazoprevir concentrations (see section 4.3). Co-administration of REYATAZ with
glecaprevir/pibrentasvir fixed-dose combination is contraindicated because of the potential increase in
the risk of ALT elevations due to a significant increase in glecapreir and pibrentasvir plasma
concentrations (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) cisapride (HOS-085610) pibrentasvir (HOS-086298) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) glecaprevir (HOS-086297) grazoprevir (HOS-108815) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) terfenadine (HOS-085607) lurasidone (HOS-086148) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8c472f02d161fbf877b321685a02acd6721db094612098433562a9a244834b35 · Zeichen 315–1385 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 60–61
HOS-112205 · Präparat HOS-093615
60
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
SEDATIVES
Benzodiazepines
Midazolam Midazolam and triazolam are extensively Co-administration of
Triazolam metabolised by CYP3A4. Co- REYATAZ with triazolam or
administration with REYATAZ may cause orally administered midazolam
a large increase in the concentration of is contraindicated (see
these benzodiazepines. No drug interaction section 4.3), whereas caution
study has been performed for the co- should be used with co-
administration of REYATAZ with administration of REYATAZ
benzodiazepines. Based on data for other and parenteral midazolam. If
CYP3A4 inhibitors, plasma concentrations REYATAZ is co-administered
of midazolam are expected to be with parenteral midazolam, it
significantly higher when midazolam is should be done in an intensive
given orally. Data from concomitant use of care unit (ICU) or similar
parenteral midazolam with other protease setting which ensures close
inhibitors suggest a possible 3-4-fold clinical monitoring and
increase in midazolam plasma levels. appropriate medical
management in case of
respiratory depression and/or
prolonged sedation. Dosage
adjustment for midazolam
should be considered,
especially if more than a single
dose of midazolam is
administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage f250a428a827d9b8c4affc6ad5576eaf38f2ba45cfd4b7267c714a1454016b78 · Zeichen 76500–79065 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5–6
HOS-112520 · Präparat HOS-093697
5
Midazolam
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines
metabolised via CYP3A4 (alprazolam, triazolam) should be considered when co-administering these
medicinal products with EMEND (125 mg/80 mg).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alprazolam (HOS-086171) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 9283b56525cd8268f7f278eb5e5e54ff213c77eec0da0f29a8d07e58a1efddb8 · Zeichen 4593–4842 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 23
HOS-112579 · Präparat HOS-093697
Midazolam
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines
metabolised via CYP3A4 (alprazolam, triazolam) should be considered when co-administering these
medicinal products with EMEND (125 mg/80 mg).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alprazolam (HOS-086171) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage deeec11f3bbc3a506663309d02a6e82291238b60c2eed802f554c1d2491f51a9 · Zeichen 4541–4787 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 40 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 8
HOS-114243 · Präparat HOS-094063
Midazolam and other benzodiazepines metabolised by CYP3A4
In a study in healthy volunteers, posaconazole oral suspension (200 mg once daily for 10 days)
increased the exposure (AUC) of intravenous midazolam (0.05 mg/kg) by 83 %. In another study in
healthy volunteers, repeat dose administration of posaconazole oral suspension (200 mg twice daily
for 7 days) increased the Cmax and AUC of intravenous midazolam (0.4 mg single dose) by an average
of 1.3 and 4.6-fold (range 1.7 to 6.4-fold), respectively; Posaconazole oral suspension 400 mg twice
daily for 7 days increased the intravenous midazolam Cmax and AUC by 1.6 and 6.2-fold (range 1.6 to
7.6-fold), respectively. Both doses of posaconazole increased Cmax and AUC of oral midazolam (2 mg
single oral dose) by 2.2 and 4.5-fold, respectively. In addition, posaconazole oral suspension (200 mg
or 400 mg) prolonged the mean terminal half-life of midazolam from approximately 3-4 hours to
8-10 hours during co-administration.
Due to the risk of prolonged sedation, it is recommended that dose adjustments of benzodiazepine that
are metabolised by CYP3A4 (e.g. midazolam, triazolam, alprazolam) should be considered when
posaconazole is administered concomitantly (see section 4.4) and also refer to the SmPC of the
corresponding benzodiazepines metabolised by CYP3A4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alprazolam (HOS-086171) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 43f1fb0eee43c47da9c703a407d1a5cb733f223a13639fbdf525190edc314902 · Zeichen 6006–7328 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 100 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-114293 · Präparat HOS-094063
Midazolam and other benzodiazepines metabolised by CYP3A4
In a study in healthy volunteers posaconazole oral suspension (200 mg once daily for 10 days)
increased the exposure (AUC) of intravenous midazolam (0.05 mg/kg) by 83 %. In another study in
healthy volunteers, repeat dose administration of posaconazole oral suspension (200 mg twice daily
for 7 days) increased the Cmax and AUC of intravenous midazolam (0.4 mg single dose) by an average
of 1.3- and 4.6-fold (range 1.7 to 6.4-fold), respectively; Posaconazole oral suspension 400 mg twice
daily for 7 days increased the intravenous midazolam Cmax and AUC by 1.6 and 6.2-fold (range 1.6 to
7.6-fold), respectively. Both doses of posaconazole increased Cmax and AUC of oral midazolam (2 mg
single oral dose) by 2.2 and 4.5-fold, respectively. In addition, posaconazole oral suspension (200 mg
or 400 mg) prolonged the mean terminal half-life of midazolam from approximately 3-4 hours to
8-10 hours during co-administration.
Due to the risk of prolonged sedation, it is recommended that dose adjustments of benzodiazepine that
are metabolised by CYP3A4 (e.g. midazolam, triazolam, alprazolam) should be considered when
posaconazole is administered concomitantly (see section 4.4) and also refer to the SmPC of the
corresponding benzodiazepines metabolised by CYP3A4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alprazolam (HOS-086171) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 546b40d8449173321b39f4d5011a8ef25cc8287a316f66151e19ade75c245d33 · Zeichen 5426–6748 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.